Clinical trial readout dates for Amgen Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.
The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.
| Phase 3 Apremilast Plaque Psoriasis · NCT06088199 | August 2026 Primary data collected |
| Phase 3 Dazodalibep Sjogren's Syndrome · NCT06104124 | July 2026 Primary data collected |
| Phase 1/2 sotorasib KRAS p.G12C Mutant Advanced Solid Tumors · NCT03600883 | May 2026 Primary data collected |
| Phase 3 ABP 234 Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) · NCT06430866 | December 2026 Ongoing |
| Phase 1/2 AMG 732 Thyroid Eye Disease · NCT06401044 | January 2027 Ongoing |
| Phase 3 Maridebart Cafraglutide Obesity · NCT06858839 | January 2027 Ongoing |
| Phase 3 Maridebart cafraglutide Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight · NCT06858878 | January 2027 Ongoing |
| Phase 2 Inebilizumab Neuromyelitis Optica Spectrum Disorder · NCT05549258 | April 2027 Recruiting |
| Phase 3 Ocrelizumab (US) Relapsing-remitting Multiple Sclerosis (RRMS) · NCT06700343 | April 2027 Ongoing |
| Phase 3 Maridebart cafraglutide Obesity Disease · NCT06987695 | April 2027 Ongoing |
These dates have elapsed; the company may have reported, or guidance may have shifted.
| Phase 1/2 Anvumetostat Advanced MTAP-null Solid Tumors · NCT05094336 | November 2026 Ongoing |
Amgen Inc. reported $13.19B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-04). It reported net income of $3.86B for that quarter.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-03 |